Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, NIH, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA.
Biomark Med. 2010 Dec;4(6):799-803. doi: 10.2217/bmm.10.92.
Proteomics technologies have revolutionized cell biology and biochemistry by providing powerful new tools to characterize complex proteomes, multiprotein complexes and post-translational modifications. Although proteomics technologies could address important problems in clinical and translational cancer research, attempts to use proteomics approaches to discover cancer biomarkers in biofluids and tissues have been largely unsuccessful and have given rise to considerable skepticism. The National Cancer Institute has taken a leading role in facilitating the translation of proteomics from research to clinical application, through its Clinical Proteomic Technologies for Cancer. This article highlights the building of a more reliable and efficient protein biomarker development pipeline that incorporates three steps: discovery, verification and qualification. In addition, we discuss the merits of multiple reaction monitoring mass spectrometry, a multiplex targeted proteomics platform, which has emerged as a potentially promising, high-throughput protein biomarker measurements technology for preclinical 'verification'.
蛋白质组学技术通过提供强大的新工具来描述复杂的蛋白质组、多蛋白复合物和翻译后修饰，彻底改变了细胞生物学和生物化学。尽管蛋白质组学技术可以解决临床和转化癌症研究中的重要问题，但试图使用蛋白质组学方法在生物体液和组织中发现癌症生物标志物的尝试在很大程度上并不成功，并且引起了相当大的怀疑。美国国立癌症研究所通过其临床蛋白质组癌症技术，在促进蛋白质组学从研究到临床应用的转化方面发挥了主导作用。本文重点介绍了建立一个更可靠和有效的蛋白质生物标志物开发管道，该管道包含三个步骤：发现、验证和资格。此外，我们还讨论了多重反应监测质谱法的优点，这是一种多重靶向蛋白质组学平台，它已成为一种有前途的高通量蛋白质生物标志物测量技术，可用于临床前的“验证”。
